Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

Roche's stock climbed after Morgan Stanley upgraded the pharmaceutical giant to Overweight, boosting its price target due to strong prospects for its breast-cancer drug, giredestrant. The bank anticipates giredestrant will achieve higher sales and faster market penetration than previously expected, significantly impacting Roche's earnings. Despite the positive outlook and robust core business performance, the article notes that Roche's current stock valuation is nearly 40% above its intrinsic value, implying that future gains will rely heavily on successful execution and favorable FDA decisions regarding giredestrant.